Duration of Postop Analgesia After Inguinal Hernia Surgery Treated with TAP Block Vs II/IH Nerve Block

NCT06812741 on ClinicalTrials.gov Phase 3 Pakistan Navy Station Shifa Hospital (academic or other) Started 2024-02-09 Completed

Riskier than 12% of active trials

Model scores of the 29,894 trials active now.

Model score 8% for any early termination, 4% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 14% of the time (741 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

How it ended

Completed on 2024-07-28, after 2024-02-09 start.

The score above never used this outcome: finished trial that started in 2015 or later: the model never saw it during training.

Termination over time, as the model saw it at the start

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2024-07-28. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

What moved the score

Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
Accepts healthy volunteers: No (raises risk) · Who can join
Phase: 3 (lowers risk) · Design
Primary purpose: prevention (lowers risk) · Design
Sponsor type: academic or other (raises risk) · Sponsor's track record
Responsible party: principal investigator (lowers risk) · Design
Design: parallel (raises risk) · Design
Disease area, cancer: No (lowers risk) · Disease area
Drug's FAERS reports marked serious: 66.7% (lowers risk) · Drug's FDA history
Minimum age: 18 (raises risk) · Who can join
Drug's FAERS reports with a death: 5.2% (lowers risk) · Drug's FDA history
Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: patientstreatedsurgeryblockcardiac
Phrases that lowered it: hernia45analgesiacomparisonabdominal
Trials the sponsor started in the prior 2 years: 3 (raises risk) · Sponsor's track record
Has a data monitoring committee: No (lowers risk) · Design
Maximum age: 60 (lowers risk) · Who can join
Keywords listed: 25 (raises risk) · Design
Number of arms: 2 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

The trial

Design

Phase: 3 (typical: 2)
Number of arms: 2
Allocation: randomized
Design: parallel
Primary purpose: prevention (typical: treatment)
Blinding: none
Has a data monitoring committee: No (typical: 56% yes)
Responsible party: principal investigator (typical: sponsor)
Collaborators: 0
Keywords listed: 25 (typical: 1)

Who can join

Minimum age: 18
Maximum age: 60 (typical: 71)
Sex: all
Accepts healthy volunteers: No (typical: 9% yes)

Sponsor's track record

Sponsor type: academic or other
Sponsor's past trials: 3 (typical: 32)
Sponsor's past termination rate: 0% (typical: 9.9%)
Trials the sponsor started in the prior 2 years: 3 (typical: 19)

Drug's FDA history

Drugs with FDA adverse-event history: 1
Drug has FAERS history: Yes (typical: 64% yes)
Drug's FAERS reports before start: 15939 (typical: 2148)
Drug's FAERS reports in the prior 12 months: 1017 (typical: 412.5)
Drug's FAERS reports marked serious: 66.7% (typical: 85.6%)
Drug's FAERS reports with a death: 5.2% (typical: 15.9%)

Disease area and drugs

Disease areas: none of the 14 tracked areas
Drugs matched to FDA substances: bupivacaine

Typical values are among the trials active now. Sponsor and drug history are counted only up to this trial's start date.

Similar finished trials

Ultrasound-guided Ilioinguinal/Iliohypogastric Nerve Block NCT05559437 · started 2022 · scored riskier than 8% of active trials completed
IINB vs. QLB for Elective Open Inguinal Herniorrhaphy NCT03007966 · started 2017 · scored riskier than 96% of active trials completed
Post-operative Analgesic Effects of Dexamethasone Added to Bupivacaine in Transversusabdominis Plane (TAP) Block NCT03863977 · started 2019 · scored riskier than 7% of active trials completed
Fascia Transversalis Versus Transversus Abdominis Plane Block for Children Undergoing Inguinal Hernia Surgery NCT06326944 · started 2024 · scored riskier than 7% of active trials completed
Dexmedetomidine to Levobupivacaine for Transversus Abdominis Plane Block in Elderly Patients Undergoing Inguinal Hernia Repair Surgery NCT04971759 · started 2019 · scored riskier than 11% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.